NIPA like domain containing 3Genealiases: DJ462O23.2 · NPAL3 · SLC57A5
Q-omics provides the consensus-scored NIPAL3 profile across patient tissues and cancer cell-line models. NIPAL3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NIPAL3 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, NIPAL3 RNA expression shows 19,994 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where NIPAL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIPAL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIPAL3 survival associations across molecular data types. NIPAL3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIPAL3 RNA expression–survival associations across cancer types. High NIPAL3 expression shows unfavorable associations in LGG and HNSC, but favorable associations in KIRC, THCA, SKCM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NIPAL3 RNA expression.
This table summarizes NIPAL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NIPAL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIPAL3 shows lower tumor expression in LUAD, KICH, LUSC and KIRC and higher tumor expression in LIHC and CHOL. The LUAD box plot shows higher NIPAL3 RNA expression in normal versus tumor tissue (log2 FC = −0.740, t-test p < 0.001).
This table shows molecular features associated with NIPAL3 in patient tissues and cancer cell lines. In patient samples, NIPAL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NIPAL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
